Dissecting the heterogeneity of triple-negative breast cancer.
about
Cas proteins: dodgy scaffolding in breast cancerTrial watch - inhibiting PARP enzymes for anticancer therapyBRCA1 and estrogen/estrogen receptor in breast cancer: where they interact?Oncogenes induce the cancer-associated fibroblast phenotype: metabolic symbiosis and "fibroblast addiction" are new therapeutic targets for drug discoveryNovel therapeutic strategies for patients with triple-negative breast cancerSortilin is associated with breast cancer aggressiveness and contributes to tumor cell adhesion and invasionTargeting the EGFR/PCNA signaling suppresses tumor growth of triple-negative breast cancer cells with cell-penetrating PCNA peptidesRole of SMC1 in overcoming drug resistance in triple negative breast cancerA synthetic triterpenoid CDDO-Im inhibits tumorsphere formation by regulating stem cell signaling pathways in triple-negative breast cancerA phase II study of UCN-01 in combination with irinotecan in patients with metastatic triple negative breast cancer.Integrated genomic analysis of triple-negative breast cancers reveals novel microRNAs associated with clinical and molecular phenotypes and sheds light on the pathways they controlActive kinase profiling, genetic and pharmacological data define mTOR as an important common target in triple-negative breast cancer.Cisplatin and gemcitabine as the first line therapy in metastatic triple negative breast cancer.Meta-analysis on the association between pathologic complete response and triple-negative breast cancer after neoadjuvant chemotherapymicroRNA expression profiling identifies a four microRNA signature as a novel diagnostic and prognostic biomarker in triple negative breast cancersTrop-2-targeting tetrakis-ranpirnase has potent antitumor activity against triple-negative breast cancerAHNAK suppresses tumour proliferation and invasion by targeting multiple pathways in triple-negative breast cancer.Cellular heterogeneity profiling by hyaluronan probes reveals an invasive but slow-growing breast tumor subset.Increased macroH2A1.1 expression correlates with poor survival of triple-negative breast cancer patientsBI-RADS 3-5 microcalcifications: prediction of lymph node metastasis of breast cancerA prognostic model of triple-negative breast cancer based on miR-27b-3p and node statusMetabolic Portraits of Breast Cancer by HR MAS MR Spectroscopy of Intact Tissue Samples.Mismatch repair deficiency endows tumors with a unique mutation signature and sensitivity to DNA double-strand breaks.The metastatic potential of triple-negative breast cancer is decreased via caloric restriction-mediated reduction of the miR-17~92 clusterERCC1 polymorphisms as prognostic markers in T4 breast cancer patients treated with platinum-based chemotherapyTriple-negative vimentin-positive heterogeneous feline mammary carcinomas as a potential comparative model for breast cancer.ΔNp63 promotes stem cell activity in mammary gland development and basal-like breast cancer by enhancing Fzd7 expression and Wnt signalling.The treatment and survival of patients with triple negative breast cancer in a London populationA Novel Subset of Human Tumors That Simultaneously Overexpress Multiple E2F-responsive Genes Found in Breast, Ovarian, and Prostate CancersPredictors of Chemosensitivity in Triple Negative Breast Cancer: An Integrated Genomic Analysis.Histological Analysis of γδ T Lymphocytes Infiltrating Human Triple-Negative Breast Carcinomas.High-resolution imaging mass spectrometry reveals detailed spatial distribution of phosphatidylinositols in human breast cancer.Differential activation of Wnt-β-catenin pathway in triple negative breast cancer increases MMP7 in a PTEN dependent manner.Re-engineered p53 activates apoptosis in vivo and causes primary tumor regression in a dominant negative breast cancer xenograft model.FOXF2 deficiency promotes epithelial-mesenchymal transition and metastasis of basal-like breast cancerFolate receptor-α (FOLR1) expression and function in triple negative tumorsTranscriptome analysis of Wnt3a-treated triple-negative breast cancer cells.p53 Family Members Regulate Phenotypic Response to Aurora Kinase A Inhibition in Triple-Negative Breast CancerSilencing β3 Integrin by Targeted ECO/siRNA Nanoparticles Inhibits EMT and Metastasis of Triple-Negative Breast Cancer.Stress hormones reduce the efficacy of paclitaxel in triple negative breast cancer through induction of DNA damage
P2860
Q21146639-84202B82-3375-4D15-B6F9-A3EAE2FDA183Q26745673-87C3E90B-FE09-452F-9B3D-99C2A1FA1BC1Q26822737-77438A3B-6BFA-4223-8FB1-8D1A25091143Q26851813-F9A95712-C08B-448F-8F2B-F7015782DF71Q28067436-BF3B1DAF-ED3C-4325-996B-9850A50FCFAFQ28260431-0ADC5000-406F-4FF6-A543-066AB53DC5EDQ28486075-907D4188-492C-4A5C-8877-58E637CD3F0FQ28533198-0DB2528C-BACC-4D32-AA87-622A5D4E7D33Q28543036-99F5F84D-DDB3-4684-83CE-65FB847A1CAAQ30422919-285ED64F-1DEF-4923-9AC9-8F6A085A6E55Q30577477-22E8721A-C09A-4783-B1B7-339DE783BB12Q30582030-BA450F0E-F72A-40DD-AF92-0EE14B1CE57AQ33415281-1FAF9FF5-EF78-42BB-B013-84C1979B760EQ33573055-8857B0B6-0993-4A22-80FE-77E9BFC47BFCQ33576814-E082B6DF-04DC-4022-BF7E-7EE6A787E7D4Q33587482-680AE0BE-9BDF-4DF2-968D-B1DA5B095D01Q33667940-1ADA84AE-7814-400E-BA9C-EE354929D62BQ33674704-F9A5291C-8EBC-447A-84ED-D4E2398675BEQ33727273-57101034-CF10-4E15-AA5D-3D49A9A4086EQ33728272-2EC94C0B-D03F-416E-8532-0B252260A98DQ33779774-70987A8B-5205-44C5-9056-D70E0EF6E609Q33844930-0BC7AF60-AF6B-4DEE-AD65-09C9B50BD3D7Q34077139-D5678081-130D-4A38-BA3B-7018970E9D44Q34150285-32EE81E3-D54C-4E8E-B9AA-1EB5B635E2FEQ34256001-55A0C96D-ED39-49C1-827A-ED80DEA25073Q34269541-92A09962-69C9-4B1F-BF59-3F7DA318F797Q34283057-858D64B3-0CD3-4ED3-87C8-3769A583B312Q34302752-A0A20E59-A98E-4D4D-89A2-1FAFC08DDB91Q34456552-5978EC17-75D3-448A-B103-02B19DECBE1DQ34547261-49BCDE92-E030-44D0-86E1-15507F132AA1Q34668723-0A86EB7A-BA24-4FB5-8B0F-6D2970F616D3Q34803382-4380D980-4276-44FA-9158-2D9EAB1D63B5Q35021758-E03B85CB-2EB2-45C9-962A-FFE946A54226Q35073239-CC595919-454E-4C3F-95D1-4B37476377E6Q35180874-802512A0-5000-4D0E-8250-02C1299A9E01Q35225064-4F299DB3-C40B-4206-9DD4-0DDB10E9A14DQ35300556-AE41216A-32AC-48CF-B9D6-DB2C01864084Q35587605-78AB62CC-0B5B-4FE1-9419-6A5E467FA4D7Q35674830-D0834CCF-AC73-43CC-BBC8-1346C3B279FAQ35677932-79A21CBB-DCB8-47B8-95E6-866EDA1BB2C6
P2860
Dissecting the heterogeneity of triple-negative breast cancer.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Dissecting the heterogeneity of triple-negative breast cancer.
@en
Dissecting the heterogeneity of triple-negative breast cancer.
@nl
type
label
Dissecting the heterogeneity of triple-negative breast cancer.
@en
Dissecting the heterogeneity of triple-negative breast cancer.
@nl
prefLabel
Dissecting the heterogeneity of triple-negative breast cancer.
@en
Dissecting the heterogeneity of triple-negative breast cancer.
@nl
P2093
P50
P356
P1476
Dissecting the heterogeneity of triple-negative breast cancer.
@en
P2093
Andrew Tutt
Christos Sotiriou
Hatem A Azim
Ian Bradbury
José Baselga
Judith M Bliss
Kamal S Saini
Otto Metzger-Filho
Paul Ellis
P304
P356
10.1200/JCO.2011.38.2010
P407
P577
2012-03-26T00:00:00Z